Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Action agonists, stimulants, inhibitors |
Mechanism CD2 agonists(T-cell surface antigen CD2 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), ULBP2 inhibitors(UL16 binding protein 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Preclinical | Canada | 18 Nov 2025 | |
| Solid tumor | Preclinical | Canada | 18 Nov 2025 |






